F001 Alopecia Areata: New Therapies
DESCRIPTION
With the current interest in hair loss conditions being on the rise, it is important to understand alopecia areata as it is the most common cause of immune- mediated alopecia, affecting 2% of the USA population. The intricate pathology, patients demographics and comorbidities, and the new therapeutic options will be discussed. The team of speakers have been leaders in developing alopecia areata severity scale and therapeutic guidelines.
LEARNING OBJECTIVES
Compare and analyze novel therapies for alopecia areata
Identify patients who are eligible for novel medications considering their comorbidities
Describe therapeutic guidelines for alopecia areata, including dosing, duration of treatment and clinical prognosis
DIRECTOR
Natasha Atanaskova Mesinkovska, PhD, MD, FAAD
DISCLOSURES
Natasha Atanaskova Mesinkovska, PhD, MD, FAAD
AbbVie – Investigator(No Compensation Received); Arcutis, Inc. – Investigator(No Compensation Received); Arena Pharmaceuticals – Advisory Board(Honoraria), Investigator(No Compensation Received); Concert Pharmaceuticals – Advisory Board(Honoraria); Eli Lilly – Speaker(Honoraria); Kyowa Hakko Kirin Pharma, Inc. – Investigator(No Compensation Received); La Roche-Posay Laboratorie Pharmaceutique – Advisory Board(Honoraria); Lilly ICOS LLC – Advisory Board(Honoraria), Investigator(No Compensation Received); Merz Aesthetics – Investigator(Grants/Research Funding); Nutrafol – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding);